How Mild Is Omicron Really?

Early reports that Omicron causes less-severe disease than Delta seem to be borne out, but it’s not yet clear to what extent that’s due to the variant itself versus the populations it’s infecting.

Written byDan Robitzski
| 9 min read
A person lying on a bed checks the reading on a digital thermometer. A table with a bowl of oranges and various medications is in the background.
Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Update (May 5, 2022): A preprint currently under review at Nature suggests that the Omicron variant may be as severe as previous variants when variables such as vaccination status are controlled for, according to Reuters.

When the Omicron variant of SARS-CoV-2 first began to spread rapidly and outcompete other variants in late 2021, it quickly became apparent that the variant was quite different than those that came before it.

Unlike Delta, which emerged in December 2020 and was linked to a massive surge in hospitalizations and deaths last year, Omicron didn’t seem to be as dangerous on the scale of individual infected people. Yet hospitals, clinics, and intensive care units have still filled up with patients as the tally of new cases and hospitalizations, currently at more than 145,000 in the United States, shattered records day after day, in no small part because a series of mutations in the virus’s ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • black and white image of young man in sunglasses with trees in background

    Dan is an award-winning journalist based in Los Angeles who joined The Scientist as a reporter and editor in 2021. Ironically, Dan’s undergraduate degree and brief career in neuroscience inspired him to write about research rather than conduct it, culminating in him earning a master’s degree in science journalism from New York University in 2017. In 2018, an Undark feature Dan and colleagues began at NYU on a questionable drug approval decision at the FDA won first place in the student category of the Association of Health Care Journalists' Awards for Excellence in Health Care Journalism. Now, Dan writes and edits stories on all aspects of the life sciences for the online news desk, and he oversees the “The Literature” and “Modus Operandi” sections of the monthly TS Digest and quarterly print magazine. Read more of his work at danrobitzski.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies